CA2550833A1 - Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent - Google Patents

Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent Download PDF

Info

Publication number
CA2550833A1
CA2550833A1 CA002550833A CA2550833A CA2550833A1 CA 2550833 A1 CA2550833 A1 CA 2550833A1 CA 002550833 A CA002550833 A CA 002550833A CA 2550833 A CA2550833 A CA 2550833A CA 2550833 A1 CA2550833 A1 CA 2550833A1
Authority
CA
Canada
Prior art keywords
tissue
response
biological
agent
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002550833A
Other languages
English (en)
French (fr)
Inventor
Allan L. Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2550833A1 publication Critical patent/CA2550833A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57581Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002550833A 2003-12-22 2004-12-22 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent Abandoned CA2550833A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53089303P 2003-12-22 2003-12-22
US60/530,893 2003-12-22
PCT/US2004/042993 WO2005062864A2 (en) 2003-12-22 2004-12-22 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent

Publications (1)

Publication Number Publication Date
CA2550833A1 true CA2550833A1 (en) 2005-07-14

Family

ID=34738610

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002550833A Abandoned CA2550833A1 (en) 2003-12-22 2004-12-22 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent

Country Status (7)

Country Link
US (1) US20090053194A1 (enExample)
EP (1) EP1706136A4 (enExample)
JP (1) JP2007521336A (enExample)
CN (1) CN1897965A (enExample)
AU (1) AU2004308378B2 (enExample)
CA (1) CA2550833A1 (enExample)
WO (1) WO2005062864A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1755661T3 (da) * 2004-05-12 2014-06-16 Brigham & Womens Hospital Gelsolin til anvendelse til behandling af infektioner
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
WO2008134727A1 (en) * 2007-04-30 2008-11-06 The Board Of Regents Of The University Of Texas System Methods and compositions for treatment of reperfusion injury and other cardiac conditions
RU2364396C2 (ru) * 2007-11-07 2009-08-20 ФГУН "Нижегородский научно-исследовательский институт гигиены и профессиональной патологии" Роспотребнадзора Способ профилактики и коррекции иммунных нарушений, вызываемых токсическими веществами
ES2531827T3 (es) 2008-01-25 2015-03-20 The General Hospital Corporation Usos terapéuticos de gelsolina en insuficiencia renal
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
US20230025377A1 (en) * 2020-02-13 2023-01-26 HLB Therapeutics Co., Ltd. Compositions and methods for treating or preventing pruritus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
EP1100529B2 (en) * 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
EP1296704A4 (en) * 2000-06-14 2005-04-27 Chanda Bhuwalka Zaveri PEPTIDES WITH PHYSIOLOGICAL ACTIVITY
JP2004525988A (ja) * 2001-05-17 2004-08-26 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ4を用いる表皮水疱症(EpidermolysisBullosa)の治療
US9056087B2 (en) * 2001-08-29 2015-06-16 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
US20060264360A1 (en) * 2002-04-12 2006-11-23 Yale University Office Of Cooperstive Research Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4

Also Published As

Publication number Publication date
WO2005062864A2 (en) 2005-07-14
JP2007521336A (ja) 2007-08-02
AU2004308378B2 (en) 2010-05-13
AU2004308378A1 (en) 2005-07-14
CN1897965A (zh) 2007-01-17
EP1706136A4 (en) 2009-09-16
EP1706136A2 (en) 2006-10-04
US20090053194A1 (en) 2009-02-26
WO2005062864A3 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
CA2475053A1 (en) Treatment of microbial infections and associated gastrointestinal disorders with thymosin .beta.4
AU2008261127A1 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta 4 (TBeta4), Analogues, Isoforms and Other Derivatives
CA2458883A1 (en) Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列lkktetを含む皮膚変性阻害ポリペプチドの使用
AU2004308378B2 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
US8716215B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
JP2007521336A5 (enExample)
US20060246057A1 (en) Treatment or prevention of damage due to radiation exposure
US20080096817A1 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
AU2002213513A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
US20040067227A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
MXPA06006849A (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
KR20070019668A (ko) 반응성 화학물질 또는 생물학적 물질 또는 독성 물질에대한 생물학적 또는 면역학적 반응들의 치료 또는 예방방법
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
CA2558039A1 (en) Treating or preventing extracellular matrix build-up
WO2006076254A2 (en) Method of treating or preventing respiratory microbial infection of respiratory tissue

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141223